Literature DB >> 25331110

Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

Paul M McKie1, John C Burnett.   

Abstract

The natriuretic peptide system (NPS) is intimately involved in cardiorenal homeostasis in health, and dysregulation of the NPS plays an important role in the pathophysiology of heart failure (HF). Indeed, the diuretic, vasorelaxation, beneficial remodeling, and potent neurohumoral inhibition of the NPS support the therapeutic development of chronic augmentation of the NPS in symptomatic HF. Further, chronic augmentation of the protective NPS and in early stages of HF may ultimately prevent the progression of HF and reduced subsequent morbidity and mortality. In the current manuscript, we review the rationale for as well as previous and current efforts aimed at chronic therapeutic augmentation of the NPS in HF.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25331110     DOI: 10.1007/s11897-014-0235-3

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  106 in total

1.  Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles.

Authors:  YiLin Ren; Jeffrey L Garvin; Oscar A Carretero
Journal:  Hypertension       Date:  2002-03-01       Impact factor: 10.190

2.  Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.

Authors:  D B Northridge; P F Currie; D E Newby; J J McMurray; M Ford; N A Boon; H J Dargie
Journal:  Eur J Heart Fail       Date:  1999-03       Impact factor: 15.534

3.  Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.

Authors:  Carolyn S P Lam; John C Burnett; Lisa Costello-Boerrigter; Richard J Rodeheffer; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2007-03-06       Impact factor: 24.094

4.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

5.  Effect of nesiritide in patients with acute decompensated heart failure.

Authors:  C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

6.  Measurement of the total proANP product in mammals by processing independent analysis.

Authors:  Ingrid Hunter; Jens F Rehfeld; Jens P Goetze
Journal:  J Immunol Methods       Date:  2011-06-15       Impact factor: 2.303

7.  Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide.

Authors:  Denise M Heublein; Brenda K Huntley; Guido Boerrigter; Alessandro Cataliotti; Sharon M Sandberg; Margaret M Redfield; John C Burnett
Journal:  Hypertension       Date:  2007-03-19       Impact factor: 10.190

8.  The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties.

Authors:  T G Flynn; M L de Bold; A J de Bold
Journal:  Biochem Biophys Res Commun       Date:  1983-12-28       Impact factor: 3.575

9.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Authors:  J L Rouleau; M A Pfeffer; D J Stewart; D Isaac; F Sestier; E K Kerut; C B Porter; G Proulx; C Qian; A J Block
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

10.  Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jim Gong; Martin P Lefkowitz; Adel R Rizkala; Jean Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  Eur J Heart Fail       Date:  2013-04-05       Impact factor: 15.534

View more
  5 in total

Review 1.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

2.  The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.

Authors:  Mattia Arrigo; Nicolas Vodovar; Hélène Nougué; Malha Sadoune; Chris J Pemberton; Pamela Ballan; Pierre-Olivier Ludes; Nicolas Gendron; Alain Carpentier; Bernard Cholley; Philippe Bizouarn; Alain Cohen-Solal; Jagmeet P Singh; Jackie Szymonifka; Christian Latremouille; Jane-Lise Samuel; Jean-Marie Launay; Julien Pottecher; A Mark Richards; Quynh A Truong; David M Smadja; Alexandre Mebazaa
Journal:  Eur Heart J       Date:  2018-05-21       Impact factor: 29.983

3.  Depressed Corin Levels Indicate Early Systolic Dysfunction Before Increases of Atrial Natriuretic Peptide/B-Type Natriuretic Peptide and Heart Failure Development.

Authors:  Ranjana Tripathi; Dong Wang; Ryan Sullivan; Tai-Hwang M Fan; Inna P Gladysheva; Guy L Reed
Journal:  Hypertension       Date:  2015-12-14       Impact factor: 10.190

Review 4.  Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.

Authors:  Jagdeep S S Singh; Chim C Lang
Journal:  Vasc Health Risk Manag       Date:  2015-06-01

Review 5.  The Biomarkers for Acute Myocardial Infarction and Heart Failure.

Authors:  Xi-Ying Wang; Fen Zhang; Chi Zhang; Liang-Rong Zheng; Jian Yang
Journal:  Biomed Res Int       Date:  2020-01-17       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.